Cue Biopharma (CUE) Accumulated Expenses (2017 - 2025)

Cue Biopharma has disclosed Accumulated Expenses across 9 years of filings, most recently posting $783000.0 for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $783000.0, down 56.79% year-over-year; the trailing twelve-month figure through Dec 2025 was $783000.0 (down 56.79% YoY), and the FY2025 annual result was $783000.0, down 56.79% from the prior year.
• Accumulated Expenses came in at $783000.0 for Q4 2025 at Cue Biopharma, down from $1.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.2 million in Q1 2024 to a low of $783000.0 in Q4 2025.
• The 5-year median for Accumulated Expenses is $3.0 million (2023), against an average of $3.0 million.
• Across the five-year window, Accumulated Expenses surged 83.19% in 2024 and tumbled 66.73% in 2025, its largest moves.
• Cue Biopharma's Accumulated Expenses stood at $2.0 million in 2021, then increased by 13.28% to $2.3 million in 2022, then decreased by 2.38% to $2.2 million in 2023, then dropped by 18.34% to $1.8 million in 2024, then sank by 56.79% to $783000.0 in 2025.
• The last three Accumulated Expenses figures came in at $783000.0 (Q4 2025), $1.9 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.